
Release date: 2024-08-07 17:12:12 Article From: Lucius Laos Recommended: 293
Capmatinib acts as a targeted therapy to stop the growth and spread of cancer cells by inhibiting MET tyrosine kinase activity. Usually, this medication is for those who do not respond to other therapies or are no longer effective.
Capmatinib brings new therapeutic hope to patients with specific non-small cell lung cancer (NSCLC) who carry exon 14 skipping mutations in the MET gene. Mutations in METex14 cause abnormally active MET proteins, which promote the growth and spread of cancer cells. As a MET inhibitor, capmatinib inhibits the proliferation and spread of cancer cells by precisely intervening in abnormal signaling pathways.
By directly targeting specific gene mutations in tumor cells, capmatinib helps to better control tumor progression, prolong patient survival, and improve quality of life. In these patients, which respond poorly to conventional chemotherapy or immunotherapy, capmatinib offers a more effective treatment option. In clinical practice, doctors prioritize the inclusion of capmatinib in the treatment regimen after genetic testing confirms the presence of a METex14 mutation.
Before purchasing and using the drug, patients should be aware of the drug interactions associated with capmatinib, which are organized as follows:
When capmatinib is used, strong inhibitors of CYP3A may increase the concentration of the drug, leading to serious adverse reactions. Concomitant use of these drugs, including but not limited to itraconazole, ketoconazole, voriconazole, atazanavir, ritonavir, clarithromycin, and grapefruit, should be avoided.
CYP3A inducers may reduce the efficacy of capmatinib, leading to reduced anti-tumor activity. Concomitant use of common inducers should be avoided, including antituberculous drugs rifampicin, rifapentine, phenytoin, carbamazepine, barbiturates, and St. John's wort.
[Warm Tips] The use of any medication is accompanied by certain risks and potential side effects, if patients experience discomfort during the process of taking the drug, please seek medical attention in time for professional help.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:1592025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:3992024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:1532025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:1712025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:1532025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:1872025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:1672025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:1622025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: